AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-16. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Carey (1940), executive officer of the American Association for the Advancement of Science and publisher of Science 1975–1987 Robert Bleiberg (1943), former publisher and managing editor of Barron's Gilman Kraft (1947), former owner and publisher of Playbill Jason Epstein (1949), editorial director of Random House and co-founder of the New York Review of Books Bernard Shir-Cliff (1949), editor of Ballantine Books and Warner Books Arthur Ochs Sulzberger (1951), publisher of The New York Times Lee Guittar (1953), former publisher of the San Francisco Examiner, The Denver Post, Dallas Times Herald, and president of USA Today Richard Goodwin Capen, Jr. (1956), former publisher of the Miami Herald; U.S. ambassador to Spain 1992–1993 Peter Mayer (1956), publisher of Overlook Press and former CEO of Penguin Books Daniel Leab (1957), historian, antiquarian and publisher book catalogues, former editor of Labor History Donald Welsh (1965), founding publisher of outdoors magazine Outside Albert Scardino (1970), publisher of The Georgia Gazette and Pulitzer Prize winner in 1984 Louis Rossetto (1971), founder and publisher of Wired magazine David Rothkopf (1977), CEO and editor of Foreign Policy magazine John R. MacArthur (1978), president and publisher of Harper's magazine, grandson of billionaire John D. MacArthur, benefactor of the MacArthur Fellows Program Jake Dobkin (1998), co-founder and publisher of Gothamist franchise
== Recent publications == Bale, Sue; V. Jones (2004). Wound Care Nursing, 2nd Edition - A Patient-Centered Approach. Mosby Ltd. ISBN 0-7234-3344-5. Bale, Sue; N. Tebble; V.J. Jones; P.Price (2004). "The benefits of implementing a new skin care protocol in nursing homes". Journal of Tissue Viability. 14 (2): 44–50. PMID 15114926. Bale, Sue; N. Tebble; P. Price (2004). "A topical metronidazole gel used to treat malodorous wounds". British Journal of Nursing. 13 (11): S4–11. PMID 15218439. Jones, V.; S. Bale; K.G. Harding (2004). Acute and chronic wound healing. In "Wound Care Essentials Practice" (S. Baronowski & E.A. Ayello, eds. Lippincott Williams and Wilkins. ISBN 1-58255-274-6.
Shriram Gadhve of All India Vegetable Growers Association (AIVGA) claims his organisation supports retail reform. He claimed that currently, it is the middlemen commission agents who benefit at the cost of farmers. He urged that the retail reform must focus on rural areas and that farmers receive benefits. Gadhve claimed, "A better cold storage would help since this could help prevent the existing loss of 34% of fruits and vegetables due to inefficient systems in place." AIVGA operates in nine states including Maharashtra, Andhra Pradesh, West Bengal, Bihar, Chhattisgarh, Punjab and Haryana with 2,200 farmer outfits as its members. Bharat Krishak Samaj, a farmer association with more than 75,000 members says it supports retail reform. Ajay Vir Jakhar, the chairman of Bharat Krishak Samaj, claimed a monopoly exists between the private guilds of middlemen, commission agents at the sabzi mandis (India's wholesale markets for vegetables and farm produce) and the small shopkeepers in the unorganised retail market. Given the perishable nature of food like fruit and vegetables, without the option of safe and reliable cold storage, the farmer is compelled to sell his crop at whatever price he can get. He cannot wait for a better price and is thus exploited by the current monopoly of middlemen. Jakhar asked that the government make it mandatory for organised retailers to buy 75% of their produce directly from farmers, bypassing the middlemen monopoly and India's sabzi mandi auction system. Consortium of Indian Farmers Associations (CIFA) announced its support for retail reform.
Sources: en.wikipedia.org
No charges have been brought against the contractor because he does not fall under military jurisdiction; it is questionable whether any charges will or even can be brought against him. Donald Rumsfeld had said that army and government had only been informed in January and not in detail. On January 16, 2004, a press release was issued by the United States Central Command (CENTCOM) stating that an investigation had been initiated in response to allegations of detainee abuse at an unspecified detention facility (now known to be Abu Ghraib prison). In March 2004, 6 soldiers in Abu Ghraib were charged with dereliction of duty, cruelty and maltreatment, and sexual abuse. 17 others were suspended from duty, including the seven U.S. officers who ran the prison. Also recommended for discipline was Brig. Gen Janis Karpinski, the commander of the 800th brigade. The Red Cross, which had access to these prisons, has stated that the instances of torture were not aberrations but were systemic. Some officers have attempted to defend themselves by saying that they were only doing their duty. In response to ongoing complaints, the US military initiated a program to reform the internment and treatment systems. The reforms are expected to increase safeguards for prisoners' rights, to ensure each prisoner receives a copy of their internment order, and has their charges explained to them within 72 hours. They additionally plan to publicly post information about detainees so that family members can know what happened to their loved ones. Reforms were made in March 2004.
Viral inactivation is the process of rendering a virus incapable of causing infection. It plays a critical role across multiple fields, including clinical medicine, diagnostics, research, and the food industry. In clinical practice, inactivation is essential for preventing viral transmission through blood products—such as transfusions and other biological materials—as well as in biopharmaceutical manufacturing. In diagnostic and research contexts, inactivation enables the safe study and manipulation of viruses without risking transmission to laboratory staff or healthcare personnel. Moreover, in vaccine development, inactivated viruses are employed to stimulate the host immune system, promoting the production of neutralizing antibodies. A wide range of viral inactivation techniques exist, ranging from physical removal by filtration to mechanical and chemical methods. The choice of technique depends on the specific context and intended purpose. In many situations, a combination of methods is employed—particularly when handling highly pathogenic viruses—where absolute sterility is crucial. Some of the more common viruses removed by these methods are the HIV-1 and HIV-2 viruses; hepatitis A, B, and C; and parvoviruses.
Ketoacidosis A kind of acidosis characteristic of uncontrolled diabetes. It is not uncommon among diabetics, especially type 1 diabetics. See acidosis Ketone bodies commonly called ketones—Three chemicals produced during ketosis (i.e., fat metabolism) and which are released in large quantities during abnormal fat processing. They are, together, quite acidic and if prolonged may lead to acidosis. Oddly, they are not all ketones chemically. The name is a historical leftover, but the chemical smell characteristic of ketoacidosis is an acetone (i.e., ketone) smell. Ketonuria Having ketone bodies in the urine; a warning sign of diabetic ketoacidosis (DKA). Ketone test strips can be used to detect them. Ketosis fat metabolism. It is characteristic of ordinary metabolism, when glucose is not available, but can become abnormal, leading to ketoacidosis under some conditions. It is not uncommon among diabetics, especially type 1 diabetics. Kidney disease Any one of several chronic conditions that are caused by damage to the cells of the kidney. People who have had diabetes for a long time may have kidney damage. Also called nephropathy. Kidneys organs which produce urine by excreting blood plasma and then resorbing important chemicals. Glucose and proteins are especially well resorbed, such that the presence of either is evidence of serious problems. Possibly including diabetes. The remainder is urine. Kidney threshold The point at which the blood is holding too much of a substance such as glucose (sugar) and the kidneys "spill" the excess sugar into the urine.
Methanogens rely on such enzymes to catalyze the reduction of CO2 to methane. One step in methanogenesis entails conversion of a methenyl group (formic acid oxidation state) to a methylene group (formaldehyde oxidation state). Among the hydrogenase family of enzymes, Hmd is unique in that it does not directly reduce CO2 to CH4. The natural substrate of the enzyme is the organic compound methenyltetrahydromethanopterin. The organic compound includes a methenyl group bound to two tertiary amines. The methenyl group originated as CO2 before being incorporated into the substrate, which is catalytically reduced by H2 to methylenetetrahydromethanopterin as shown. Eventually the methylene group is further reduced and released as a molecule of methane. The hydride transfer has also been shown to be stereospecific. Given that the substrate is planar the hydride originating from H2 is always added to the pro-R face. In the reverse reaction stereospecificity is maintained and the highlighted hydride is removed.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.